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Abstract
Background: Mitomycin C is a chemotherapeutic agent used in the treatment of peritoneal surface malignancies,
administered as hyperthermic intraperitoneal chemotherapy after cytoreductive surgery. Pharmacokinetic studies
have been based on analyses of blood, urine and abdominal perfusate, but actual tissue concentrations of the
drug have never been determined. Microdialysis is an established method for continuous monitoring of low-
molecular substances in tissues, and in the present study microdialysis of mitomycin C was studied in vitro and in
vivo.
Methods: Using in vitro microdialysis, relative recovery was determined when varying drug concentration,
temperature and perfusion flow rate. In vivo microdialysis was performed in rats to verify long-term stability of
relative recovery in four compartments (vein, peritoneum, extraperitoneal space and hind leg muscle).
Subsequently, intravenous and intraperitoneal bolus infusion experiments were performed and pharmacokinetic
parameters were calculated.
Results: In vitro, compatibility of mitomycin C and microdialysis equipment was demonstrated, and relative
recovery was stable over an adequate concentration range, moderately increased by raising medium temperature
and increased when flow rate was reduced, all according to theory. In vivo, stable relative recovery was observed
over seven hours. Mitomycin C exhibited fast and even distribution in rat tissues, and equal bioavailability was
achieved by intravenous and intraperitoneal infusion. The half-life of mitomycin C calculated after intravenous
infusion was 40 minutes.
Conclusions: Mitomycin C concentration can be reliable monitored in vivo using microdialysis, suggesting that this
technique can be used in pharmacokinetic studies of this drug during hyperthermic intraperitoneal chemotherapy.
Background
The chemotherapeutic agent mitomycin C (MMC) has
previously been used in treatment of a wide specter of
malignancies, in particular gastrointestinal, lung, head
and neck and gynecological cancer [1]. Although mostly
replaced by drugs with higher response rate and less
toxicity, it still plays a role in curative treatment of anal
cancer in combination with 5-flurouracil and radiation
therapy and is also used in palliative chemotherapy
[2,3]. The wide clinical anti-cancer effect in combination
with specific properties such as non-cell cycle specific
and direct cytotoxic effect has also rendered MMC an
attractive drug for use by topical administration, utilized
in the treatment of as diverse malignancies as bladder
cancer and certain tumors of the eye [4,5]. During the
last two decades MMC has also gained importance in
the treatment of peritoneal surface malignancies, in par-
ticular pseudomyxoma peritonei (PMP), a low-grade
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malignant disease characterized by growth of mucinous
tumors on the peritoneal surface [5-7]. PMP is treated
by a two step strategy; surgical cytoreduction aimed to
remove all macroscopic tumor and subsequent adminis-
tration of MMC by hyperthermic intraperitoneal che-
motherapy (HIPEC) for elimination of residual
microscopic disease and free tumor cells [8-10].
Although the efficacy of HIPEC has not been proven in
randomized controlled trials, the use of this treatment
strategy has in recent years been extended to include
selected patients with peritoneal carcinomatosis from
more aggressive malignancies, mainly colorectal cancer
[11,12].
In peritoneal surface malignancies the peritoneum is
considered to be a relative barrier against locally inva-
sive growth and systemic tumor spread. As long as the
disease is confined to the abdominal cavity, local admin-
istration of MMC in the form of HIPEC is an attractive
principle, since high intraabdominal drug concentration
is achieved relative to systemic absorption, which is the
main dose-limiting factor. Pharmacologic studies of
MMC during HIPEC have hitherto been based on con-
centration analysis of blood, urine and abdominal perfu-
sate collected during the procedure, but actual tissue
concentrations have never been measured [13-16].
Microdialysis (MD) is a technique which enables con-
tinuous monitoring of the free extracellular concentra-
tion of solutes in tissues [17,18]. In MD, small-caliber
probes with a semipermeable membrane connected to
inflow and outflow tubes are perfused at a low flow rate
with a liquid of osmotic properties similar to extracellu-
lar fluid. Small molecules are passively exchanged across
the membrane between the perfusate and probe sur-
roundings along the concentration gradient, and dialy-
sate is collected from the outflow tube and the
concentration of the solute in question is determined.
Because of the continuous flow through the MD probe,
concentration equilibrium over the membrane will never
occur. A key step in MD-experiments is therefore cali-
bration of the probe to determine relative recovery (RR),
the ratio between the concentration in dialysate and the
free extracellular concentration of the solute [19,20]. RR
is determined by numerous factors, of which the most
important are the perfusion flow rate, the area and per-
meability of the probe membrane and physiologic prop-
erties of the medium surrounding the membrane [21].
Because of the joint complexity of the factors which
determine RR, individual calibration of the probes is
required in each experiment [21,22].
In the present work a set of in vitro experiments was
carried out, verifying compatibility of relevant MD
equipment and MMC and showing that RR was influ-
enced according to theory when perfusion flow rate,
temperature or solute concentration were varied. In vivo
MD was then performed to assess whether stable RR
could be achieved over an adequate period of time, and
finally the tissue distribution of MMC in rats following
intravenous (i.v.) and intraperitoneal (i.p.) infusions was
studied, allowing subsequent analysis of important phar-
macokinetic properties of MMC.
Methods
Solutions and Standards
MMC (Medac, Hamburg, Germany) was dissolved in
Glucose 5% to a stock concentration of 3 mM (1 mg/
ml), aliquoted and stored in liquid nitrogen. Calibrators
at 100, 10, 1 and 0.1 μM were made up in Ringer’s-
Acetate (R-A) (Fresenius Kabi, Halden, Norway) and
stored at -70°C for up to two years without notable
degradation. Aliquots of these calibrators were thawed,
diluted, and included in each analytical series for cali-
bration and quality control. MMC in microdialysates
was quantified against calibrators in R-A. The same cali-
brators were diluted in rat plasma at the day of use for
quantification of MMC in plasma samples. The internal
standard solution was 5 μM tinidazole (T3021, Sigma-
Aldrich Company Ltd, St. Louis, MO, USA) dissolved in
R-A. Ethyl acetate, hexane and HPLC grade methanol
were from Merck (Darmstadt, Germany). All aqueous
reagents were made up in water purified through a
Milli-Q UF-PLUS system (MillPore Corp., Bedford, MA,
USA).
Determination of mitomycin C concentrations in plasma
and microdialysates
MMC concentrations in plasma were determined by
reversed phase high performance liquid chromatography
(HPLC) after solid-phase extraction (SPE). The analyti-
cal method and routines for sample handling was based
on previously published studies [23-25]. Some modifica-
tions to the methods were made, e.g. the internal stan-
dard used was no longer available and adaptation to
differences in equipment and instruments used. Chro-
matographic analysis was performed on an Agilent 1100
system (Agilent Technologies, Santa Clara, California,
USA) with a G1311A Quaternary pump, G1379A degas-
ser, G1313A autosampler, G1316A Thermostated Col-
umn compartment and a G1365B Multi-Wavelength
Detector. System control and data acquisition and inte-
gration were performed by Chemstation software Rev. B.
02.01. The mobile phase buffer was a 20 mM potassium
phosphate buffer pH 7.0. The chromatography system
was set up with buffer/methanol: 90/10 in reservoir A
and buffer/methanol: 60/40 in reservoir B delivered in
equal portions with a flow rate of 0.5 ml/min at 50°C.
The column used for separation was a Supelcosil LC-18,
150 × 3 mm with 3 μm particles protected by a 20 × 2.1
mm guard column (Supelco, Bellefonte, PA, USA).
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Tinidazole was eluted at 2.8 minutes and MMC at 4.2
minutes, followed by a 4-minute washout with 100% B
to eliminate late eluting peaks. One sample was injected
every 15 minutes. When analyzing microdialysates no
sample preparation was necessary. Ten μl of mobile
phase A was added to 10 μl of dialysate and 15 μl of the
mixture was injected. For these samples the washout
with 100% B was not required, and samples could be
injected every 5 minutes. For extraction of plasma sam-
ples, 1-ml Isolute SPE columns containing 25 mg of
endcapped C18 sorbent were used (International Sor-
bent Technology LTD, Hengoed Mid Glamorgan, UK).
To each 25-μl plasma sample, 150 μl of internal stan-
dard solutions and 25 μl R-A (or calibrator solution)
were added. All plasma samples were split and extracted
in duplicate by loading approximately half of the volume
onto each of two SPE-columns. All steps up to the sec-
ond wash (5% methanol) were performed without
vacuum, the remaining steps were performed using gen-
tle vacuum to pull the liquids through the columns. The
columns were preconditioned with 1 ml methanol and 1
ml water. After loading, columns were washed with 0.5
ml R-A, 0.2 ml 5% methanol in water, and 0.2 ml hex-
ane. Columns were dried by flushing with air for 2-3
minutes prior to elution using two times 100 μl of a 50/
50 mixture of methanol and ethyl acetate. The eluates
were evaporated to dryness for 30 minutes in a vacuum
centrifuge. The residues were dissolved in 25 μl of
mobile phase A, centrifuged and 15 μl of sample was
injected onto the HPLC system.
The HPLC assays were run with the acceptance/rejec-
tion criteria suggested by Shah et al [26,27]. The lower
limit of quantization for the determination of total
plasma concentrations of MMC was 0.1 μM. The upper
limit was 4 μM. Within this range the method had a
median accuracy of 100% (range 92%-111%), with a pre-
cision of 0.1%-6%. The lower detection limit for the
determination of MMC in microdialysates was 0.02 μM.
The tested upper limit was 100 μM, but the assay was
set up with 10 μM as upper limit for the in-vivo studies.
The method had a median accuracy of 99% (range 97%-
103%), with a precision from 2% at MMC concentration
100 μM to 13% at MMC concentration 0.02 μM.
Microdialysis
MD was performed using CMA/20 Elite microdialysis
probes with membrane length 10 mm, diameter 0.5 mm
and molecular cutoff 20 kDa. A CMA/100 syringe
pump, 1-ml glass micro syringes and a CMA/140 frac-
tion collector, all from CMA/Microdialysis AB (Solna,
Sweden) were used to administer perfusion solution and
handle collected fractions. MD fractions were collected
in glass vials, diluted 1:1 with mobile phase A and
stored at -70°C until analysis.
In vitro microdialysis in Ringer’s - Acetate
The general mathematical expression of RR is:
RR 1 C C C Cin out in m% /( ) = × −( ) −( )00 (1)
in which Cin, Cout and Cm is the concentration in per-
fusate, dialysate and the medium surrounding the probe
membrane, respectively [28]. Two experimental setups
were applied in order to compare in vitro RR by gain
(RRgain) and RR by loss (RRloss). To determine RRgain,
the probes were immersed in R-A spiked with MMC to
concentrations 1, 5 and 10 μM and perfused with blank
R-A. In this case Cin = 0, and RRgain was calculated by
the equation:
RR 1 C Cgain out m% /( ) = ×00 (2)
The same probes were used to determine RRloss by the
retrodialysis method, in which identical concentrations
of MMC in R-A were used as perfusate and the probes
were immersed in blank R-A. In this case Cm = 0, and
RRloss was calculated by the equation:
RR 1 C C Closs in out in% /( ) = × −( )00 (3)
The experiments were conducted for four hours at
37°C with flow rate 1 μl/min and sample volume 20 μl,
i.e. 12 replicates were collected from each probe.
In vitro microdialysis in plasma
To assess the influence on RR by changing the concen-
tration, perfusion flow rate and temperature, three sets
of experiments were performed with MD probes
immersed in male rat plasma spiked with MMC at con-
centrations 1.0, 2.5 and 5.0 μM. Unless otherwise stated,
the temperature in the medium was 37°C and flow rate
was 1 μl/min. All experiments were performed in tripli-
cate and the mean of three 10-μl samples was calculated
for each data point. The experiments with variable flow
rate (flow rate experiments) were performed with flow
6, 4, 2, 1 and 0.5 μl/min, and the temperature experi-
ments were performed at 37, 40, 42 and 44°C. In these
experimental setups RR was calculated using equation
(2), in which Cm was the concentration of MMC in
plasma. The zero-net flux (ZNF) method can be used
both to calculate the solute concentration and for probe
calibration, provided a stable concentration of the solute
in the medium. In ZNF the perfusate contains the solute
of interest and by varying Cin in a stepwise manner and
measuring the resulting Cout, Cm and RR can be calcu-
lated using equation (1) [29]. ΔC (=Cout-Cin) is plotted
against Cin and a linear regression line is drawn between
these points. The point of interception of the regression
line on the x-axis (ΔC = 0) is where Cin is equal to the
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free fraction of Cm, while the slope of the regression line
represents RR for the probe [30]. The ZNF-experiments
were performed with Cin 0.5, 4 and 10 μM.
Animals
Fifteen locally bred Rowett nude male rats with mean
weight 346 g (range 302-396) were used, divided into
three groups. Four animals were used to assess the sta-
bility of RR by the retrodialysis method in four different
compartments over seven hours. For pharmacokinetic
studies, six animals were given i.v. and five were given
i.p. infusions of MMC. The animals were maintained
under specific pathogen-free conditions, and food and
water were supplied ad libitum. Housing and all proce-
dures involving animals were performed according to
protocols approved by the animal care and use
committee.
Surgical procedures
Anesthesia was initialized with isoflurane (Sevorane,
Abbott Scandinavia AB, Solna, Sweden) and maintained
with subcutaneous (s.c.) injections of a mixture of tileta-
mine, 5.9 mg/ml and zolazepam, 5.9 mg/ml, (Zoletil vet,
Virbac Laboratories, Carros, France), xylazine, 9.5 mg/
ml, (Narcoxyl vet, Roche, Basel, Switzerland) and butor-
phanol, 0.23 mg/ml, (Torbugesic, Fort Dodge Labora-
tories, Fort Dodge, Iowa, USA). The initial dose of this
mixture was 0.17 ml/100 g, and maintenance doses were
0.043 ml/100 g administered hourly. On completion of
the experiments the animals were sacrificed using intra-
cardial injections of penthobarbital (Haukeland Hospital
Pharmacy, Bergen, Norway). During the experiments the
body temperature was maintained at 37°C using a
CMA/150 temperature controller (CMA/Microdialysis
AB, Solna, Sweden). Infusion catheters for administering
i.v. infusions and probes for performing MD were
inserted through the right and left pectoral muscles into
the external jugular veins through small skin incisions.
Through a small midline laparotomy, placement of the
MD probe in the extraperitoneal (XP) position in the
flank was facilitated by tunneling outside the perito-
neum with a blunt surgical probe under visual control.
The MD probe was gently pushed in position beside the
surgical probe which was then removed. MD probe or
infusion catheter placement in the peritoneal cavity was
accomplished through the abdominal wall and the mus-
cle probe was placed in the left biceps femoris muscle
through a separate skin incision. Except for the XP loca-
tion, the probes and catheters were placed using an
introducer consisting of a needle and split-tube.
Stability of relative recovery during in vivo microdialysis
To evaluate the stability of RR in the compartments
named above (vein, peritoneum, XP and muscle), three
experiments were performed for each compartment.
Because the equipment permitted only three MD probes
per experiment, all compartments could not be exam-
ined simultaneously. After surgery the probes were
flushed with R-A for 15 min at flow rate 10 μl/min, for
the rest of the experiment the flow rate was 1 μl/min.
After another 15 min with blank R-A, perfusion with
2 μM MMC in R-A was initiated and the probes were
perfused for 90 min for equilibration of the system
before start of sampling. MD was performed for seven
hours with continuous sampling of 20-μl fractions, i.e.
21 replicates were collected from each probe. To avoid
clotting on the vein probe, dalteparin 25 IE/ml (Frag-
min, Pfizer, Limoges, France) was added to the perfusate
in this probe. The concentration in the tissue being
zero, RR of each sample collected was calculated using
equation (3).
Tissue distribution of mitomycin C during intravenous
and intraperitoneal infusion
In this set of experiments, MD was performed to evalu-
ate tissue distribution of MMC in rats during and after
i.v. and i.p. bolus infusion. In the i.v. group the MD
probes were placed in the vein, XP and peritoneum
compartments and the infusion catheter in the left
external jugular vein, while the i.p. group had probes in
the vein, XP and muscle and an i.p. infusion catheter.
For equilibration after surgery, the probes were perfused
with R-A for 30 min and with 2 μM MMC in R-A for
90 min as described above. Individual calibration of the
probes by the retrodialysis method was then performed
in each experiment prior to the infusion of MMC. Four
10-μl samples were collected from each probe, and RR
was calculated using equation (3) with Cout defined as
the mean MMC-concentration in the dialysates. After
calibration, the remainder of the experiments were
performed using blank R-A as perfusate, starting with a
30 min washout of the drug. MMC 2.5 mg/kg (750 μM
in saline) was then infused over 30 min using an Asana
syringe pump (Alaris medical systems, Basingstoke, UK).
Dialysate sampling was started 6 min after infusion
start, allowing time for emptying of the dead-volume of
the probe. Continuous sampling was performed for four
hours at flow rate 1 μl/min with sample volumes of 10
μl. The tissue concentration of MMC was calculated by
reformulating equation (2), dividing the dialysate con-
centrations by RR determined by the probe calibration.
Dalteparin was added to the perfusate in the vein probe
throughout the experiments as described above. Blood
samples for plasma analyses were taken from the lesser
saphenous veins 35, 65 and 95 min after start of infu-
sion, immediately centrifuged and plasma was stored at
-70°C until analysis. To calculate the fraction of MMC
absorbed from the abdominal cavity during the i.p.
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infusion experiments, the abdomen was opened at the
end of sampling and the remaining fluid was collected
for MMC content analysis.
Calculations and statistical analysis
Pharmacokinetic parameters were determined by non-
compartmental analysis using Kinetica ver 4.4.1
(Thermo Fisher Scientific Inc, Philadelphia, PA, USA).
Statistical calculations were performed using SPSS soft-
ware version 16.0 (SPSS GmBH, Chicago, Ill). Compari-
sons of area under the curve (AUC) in vein,
peritoneum, XP, and muscle after i.v. and i.p. infusion
were performed using the Mann-Whitney test, and
p-values < 0.05 were considered significant.
Results
In vitro microdialysis in Ringer’s - Acetate
For in vivo MD the probe is routinely calibrated by the
retrodialysis method using equation (3) to calculate
RRloss, whereas the actual tissue concentration after
administration of the solute is calculated by equation
(2), dividing the dialysate concentration by RRgain.
Therefore, RRgain should be equal to RRloss for relevant
concentrations of the solute [21,22]. Mean RRgain and
RRloss for MMC using the presented experimental setup
were 62.7% and 60.1% at 1 μM, 82.9% and 75.7% at
5 μM and 72.2% and 75.7% at 10 μM, respectively
(figure 1a).
In vitro microdialysis in plasma
During in vivo administration of a solute the tissue con-
centration will usually vary over time, in HIPEC the
temperature is intentionally increased during the proce-
dure, and finally, a flow rate that results in an acceptable
RR with reasonable sample volumes must be chosen. To
evaluate the influence of these parameters on RR, three
series of in vitro experiments were performed with
MMC in rat plasma. In the flow rate experiments mean
RR increased from 18.1% at flow 6 μl/min to 72.5% at
0.5 μl/min. At 1 μl/min, RR was 50.4% at 1.0 μM, 60.8%
at 2.5 μM and 59.4% at 5.0 μM, and this flow rate was
used for the remainder of the experiments in the pre-
sent work (figure 1b). To evaluate the effect of tempera-
ture on RR during MD, the medium temperature was
varied in another set of experiments, and RR (SD) was
49.4% (5.0) at 37°C, 50.0% (9.7) at 40°C, 53.9% (10.1) at
42°C and 54.9% (10.9) at 44°C. The mean concentrations
of free MMC in plasma calculated by the ZNF method
were 0.9, 2.3 and 4.6 μM, while the total plasma concen-
trations in the same samples were 1.0, 2.5 and 5.0 μM.
RR expressed by the equations of the linear regression
lines were 69.2% at 1.0 μM, 64.0% at 2.5 μM and 65.0%
at 5.0 μM, with correlation coefficients (r2) of all three
regression lines above 0.999 (figure 1c). When
Figure 1 In vitro microdialysis of mitomycin C (MMC) . a.
Comparison of in vitro relative recovery by gain (RRgain) and RRloss.
In vitro RRgain and RRloss calculated from experiments with identical
concentrations of MMC in Ringer’s-Acetate for the individual probe.
In each experimental setup 12 replicates were collected from each
probe, with one probe for each concentration. The results are
presented as mean RR (SD). b. The effect of perfusion flow rate on
RR. The effect of perfusion flow rate on RR in three experiments
with concentrations of MMC in rat plasma of 1.0, 2.5 and 5.0 μM,
with one probe for each concentration. The flow was stepwise
reduced from 6 to 0.5 μl/min. RR represent the relation between
the dialyste concentration and total concentration of MMC. The
results are presented as mean RR (pos.SD). c. In vitro zero-net flux
(ZNF). ZNF was performed on MMC in rat plasma at concentrations
of 1.0, 2.5 and 5.0 μM, with one probe for each concentration. The
concentrations of MMC in perfusate were 0.5, 4 and 10 μM. Mean
ΔC (=Cin-Cout) with pos SD calculated from three experiments. The
interceptions of the regression lines on the x-axis are equal to the
free concentrations of MMC in plasma, while the slopes of the
regression lines represent RR for the probes.
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comparing results from ZNF and flow rate experiments
(1 μl/min), the calculated RR were relatively similar but
generally slightly higher when the ZNF method was
used.
Stability of relative recovery during in vivo microdialysis
In MD, long-term stability of RR is essential since an in
vivo experiment includes both calibration of the probes
and subsequent sampling of dialysates after administra-
tion of the solute in question. The results from in vivo
calibration by the retrodialysis method, with mean RR
(SD) calculated from 21 replicates from each probe, var-
ied between 17.6% (2.2) in the peritoneum and 31.8%
(4.4) in the vein (table 1). Figure 2 depicts RR results
from three calibration experiments performed with the
peritoneal MD probe, and illustrates both inter-experi-
ment variation, but also that RR was relatively stable for
each probe during seven hours of MD.
Tissue distribution of mitomycin C during intravenous
and intraperitoneal infusion
In the i.v. infusion experiments one of the peritoneal
MD probes suffered a technical malfunction and the
results from this probe have been omitted. In two of the
animals in this group very high Cmax values were mea-
sured in the vein (51.2 and 15.6 μM), compared with
Cmax values between 3.8-5.2 μM in the remaining four
rats. However, immediately after terminating i.v. infu-
sion the vein concentrations in all animals were almost
the same and declined according to 1. order kinetic for
the rest of the experiment. Median Cmax (μM) varied
between 5.0 (range 3.8-51.2) in vein and 7.4 (range 3.7-
7.9) in peritoneum. Median AUC (μM × min) varied
between 202 (range 144-1038) in vein and 347 (range
219-425) in peritoneum with no significant difference
between compartments. The half-life (min) of MMC in
the various compartments was calculated from the con-
centration fall in the elimination phase of the i.v. infu-
sion group, and varied between median 39.0 (range
26.2-50.4) in XP and 42.2 (range 25.4-51.2) in perito-
neum (figure 3a). In the i.p. group the concentration
curves were nearly similar in all compartments with a
variation in median Cmax (μM) between 1.51 (range
1.29-1.94) in vein and 2.41 (range 1.88-4.07) in XP.
Median AUC (μM × min) varied between 170 (range
105-229) in vein and 246 (range 165-534) in XP with no
significant difference between the compartments (figure
3b). There was no significant difference in AUC between
the i.v. and i.p. groups with respect to the vein and XP
compartments. The pharmacologic parameters derived
from the i.v. and i.p. infusion experiments are summar-
ized in table 2.
The ratio between the free concentration of MMC in
blood determined by MD, and the total plasma concen-
tration of MMC from blood samples collected at the
same time, was 0.52 (SD 0.14), (n = 31). At the end of
the experiments in the i.p. group the abdomen con-
tained mean 3.0 ml (SD 0.3) with a mean MMC concen-
tration of 1.9 μM (SD 1.3), i.e. 99.8% of the infused
MMC was absorbed from the abdominal cavity during
the experiments.
Discussion
In the present work, the results from in vitro experi-
ments have verified the feasibility of performing MD of
MMC, and shown stability of RR over a relevant con-
centration range. By in vivo calibration using the retro-
dialysis method, stable RR over seven hours were
accomplished in four tissue compartments in rats. In
the subsequent use of MD in two groups of rats receiv-
ing i.v. and i.p. bolus infusions, a relatively fast and even
distribution of MMC was observed, with no significant
differences in AUC between compartments within each
group, or when comparing compartments between the
two groups.
The symmetry between RRloss and RRgain obtained by
in vitro MD of MMC in R-A, indicated that MMC
passed freely over the probe membrane did not bind to
syringes and tubes. This is a prerequisite if measured
dialysate concentrations are to immediately and consis-
tently reflect the concentration of a solute in the med-
ium outside the probe, and for the validity of calibration
by the retrodialysis method [21]. The observed variation
in RR between the three probes used was not concentra-
tion dependent, and it was therefore interpreted to be
related to a certain individual variation in membrane
permeability between the probes, underscoring the
necessity for individual probe calibration [19].
Both the flow rate and ZNF experiments allowed for
evaluation of stability of RR over the concentration
range 1.0-5.0 μM, which is a relevant interval based on
measured plasma-concentrations in patients during
HIPEC [6]. RR obtained by the ZNF method was almost
identical in the three concentrations studied, as illu-
strated by the parallel slopes of the regression lines (fig-
ure 1c). In the flow rate experiments, mean RR at 2.5
and 5.0 μM were also very similar for all flow rates,
Table 1 Relative recovery by loss over seven hours in
jugular vein, peritoneum, XP and biceps femoris muscle.
Animal number Vein Peritoneum XP Muscle
1 np 26.7 (1.4) 22.4 (3.9) 23.5 (1.6)
2 20.9 (3.4) np 23.0 (2.3) 28.9 (3.1)
3 31.5 (2.9) 29.5 (2.1) np 27.2 (1.9)
4 31.8 (4.4) 17.6 (2.2) 28.5 (1.1) np
XP = extraperitoneal space, np = not performed.
Results are expressed as mean (SD) of 21 replicates per experiment and
compartment.
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Figure 2 In vivo calibration. The curves depict relative recovery by loss of 21 replicates collected over seven hours in peritoneum from three
different experiments.
Figure 3 a. Intravenous bolus infusion and b. Intraperitoneal bolus infusion. a. Semilogaritmic concentration vs. time curves of mitomycin
C (MMC) from microdialysis probes placed in vein (V), the extraperitoneal space (XP) and intraperitoneally (P) after 30 min i.v. infusion.
Microdialysis sampling started six minutes after start of infusion to allow emptying of dead volume in microdialysis probes. The results are
presented as mean (+ SD) from six experiments. The filled circles in the V diagram represent total serum MMC concentrations (+ SD). b.
Semilogaritmic concentration vs. time curves of MMC from microdialysis probes placed in V, XP and hind leg muscle (M) after 30 min i.p.
infusion. Microdialysis sampling started six minutes after start of infusion to allow emptying of dead volume in microdialysis probes. The results
are presented as mean (+ SD) from five experiments. The filled circles in the V diagram represent total serum MMC concentrations (+ SD).
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while the slightly divergent result at 1.0 μM was caused
by very low RR obtained in one of the three experi-
ments. The apparent discrepancy between RR deter-
mined by ZNF and flow rate experiments at 1 μl/min
should be interpreted in view of MMC plasma protein
binding previously shown to be approximately 10% [31].
RR determined by the ZNF method was obtained solely
by MD, i.e. reflecting the free fractions of MMC, while
in the flow rate experiments, RR was calculated by equa-
tion (2), where the dialysate concentrations were divided
by total plasma concentrations (free and protein-bound).
Equivalently, the overall difference between the free
MMC concentrations calculated by ZNF and total
plasma concentrations may also be explained by protein
binding. In summary, acceptable stability of RR in the
concentration range of 1.0-5.0 μM was demonstrated by
the in vitro experiments on MMC in plasma.
In vivo RR will partly be determined by factors likely
to vary between otherwise identical experimental setups,
such as the diffusion and clearance rate of the solute in
the probe membrane vicinity which will be influenced
by circulatory conditions of the tissue [20]. A certain
difference in membrane permeability between presumed
identical probes (i.e. the same product) as described by
others and observed in this work, will also contribute to
RR variation [19]. The variation between RR of probes
inserted in the same compartment in this work illus-
trates the importance of individual probe calibration and
hence the need of a straightforward calibration method.
Because the ZNF method is time-consuming and
requires steady-state tissue concentration of the solute it
is considered an inconvenient method for in vivo cali-
bration, whereas the retrodialysis method prior to
administration of the drug in question is fast and reli-
able and the most commonly used in vivo calibration
method [21]. A special precaution had to be taken to
achieve acceptable long-term (~7 h) stability of RR in
the vein probe, i.e. low molecular heparin was added to
the perfusate throughout the experiment to prevent a
gradual fall in RR which was observed in initial experi-
ments and probably was caused by clotting on the probe
membrane.
After i.v. bolus infusion, Cmax values were higher and
reached more rapidly than in the i.p. infusion group.
This was expected, since in the latter group the abdom-
inal cavity served as a functional reservoir wherefrom
MMC was absorbed throughout the experiments, entail-
ing a slower and more prolonged systemic exposure of
the drug compared with i.v. infusion. Since almost all
MMC infused i.p. was absorbed to the systemic circula-
tion, both i.v. and i.p. infusion represented de facto sys-
temic administration modalities. No significant
differences in AUC in the same compartments between
the two groups indicate equal bioavailability is achieved
with i.v. and i.p. infusion strategies.
With the exception of the vein compartment in the
previously mentioned two animals during ongoing i.v.
infusion, the similarity between concentration curves of
the three compartments within each experimental setup
reflects a fast end even distribution of MMC. In analogy
with conclusions drawn by other groups who have per-
formed MD on other water soluble drugs, this indicates
that measured concentrations in easily accessible muscle
tissues are representative of systemic MMC concentra-
tion [32]. Although tissue distribution was fast and even
in the examined tissues, it should be noted that local
drug efficacy and toxicity might also depend on enzy-
matic activation rates in specific tissues [33]. The half-
life could not be calculated after i.p. infusion, since 1.
order kinetic was not achieved in this group because of
continuous absorption from the abdominal cavity. The
calculated MMC half-life of 42 min following i.v. admin-
istration is somewhat higher than reported by others (25
min), but the results may not be directly comparable
since different strains of rats were used [34]. In two ser-
ies of patients treated for peritoneal carcinomatosis with
MMC administered in the form of HIPEC, mean plasma
half-lives of 76 and 84 min were found, in agreement
with the general pharmacological observation of slower
drug metabolism in larger organisms [6,14].
Conclusions
Results from the i.v. and i.p. infusion experiments con-
firmed that MD can be used to monitor MMC tissue
Table 2 Pharmacokinetic parameters calculated after intravenous and intraperitoneal bolus infusion
i.v. infusion i.p. infusion
Vein XP Peritoneum Vein XP Muscle
AUC (μM × min) 202 (144-1038) 311 (258-378) 347 (219-425) 170 (105-229) 246 (165-534) 234 (160-321)
t½ (min) 41.7 (34.2-54.6) 39.0 (26.2-50.4) 42.2 (25.4-51.2)
Cmax (μM) 5.0 (3.8-51.2) 6.6 (5.8-8.3) 7.4 (3.7-7.9) 1.5 (1.3-1.9) 2.4 (1.9-4.1) 2.1 (1.4-2.9)
tmax (min) 20-30 20-30 20-30 40-50 40-50 40-50
XP = extraperitoneal space, AUC = area under the curve, t½ = half-life, Cmax = maximal concentration, tmax = time after start of infusion until maximal
concentration with time intervals of 10 min.
The results are expressed as median (range) from six animals in the i.v. group and five animals in the i.p. group. For tmax, the results represent the time interval
with maximal concentration.
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concentrations in vivo, also illustrated by the reproduci-
ble relationship between concentrations calculated by
intravascular MD and plasma concentrations in blood
samples. The moderate increase in RR with rising tem-
perature has to be taken into consideration, and may
imply extra attention when planning and interpreting
experiments involving differences in temperature
between probe calibration and subsequent dialysate
sampling. With these precautions in mind, the use of
MD for MMC monitoring can probably be extended to
be performed experimentally in rats during HIPEC and
eventually in humans.
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